Skip to main content
SpringerLink
Log in

Costs lower with apremilast than biologics for psoriasis

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Kaplan DL, et al. Switch Rates and Total Cost of Care Associated with Apremilast and Biologic Therapies in Biologic-Naive Patients with Plaque Psoriasis. ClinicoEconomics and Outcomes Research 2020: 369-377, No. 12, 17 Jul 2020. Available from: URL: https://doi.org/10.2147/CEOR.S251775

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Costs lower with apremilast than biologics for psoriasis. PharmacoEcon Outcomes News 858, 8 (2020). https://doi.org/10.1007/s40274-020-6981-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-6981-4

Search

Navigation